Related Experiment Video
Updated: Oct 3, 2026

A Contusion Model of Severe Spinal Cord Injury in Rats
Published on: August 17, 2013
A pharmacokinetic model for quantitative evaluation of spinal cord injury with dynamic contrast-enhanced magnetic
1Department of Radiology, University of Texas at Houston Medical School, Houston, Texas 77030, USA. Mehmet.Bilgen@uth.tmc.edu
Abstract:
A multicompartment pharmacokinetic model was proposed to quantitatively describe the distribution of the contrast agent gadopentetate-dimeglumine (Gd) in an experimental spinal cord injury (SCI). Concentration of Gd was measured in different compartments with in vivo dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the acute phase of injury. The concentration data for each rat was fitted to the model to estimate transfer rates between different compartments. The results indicate: 1) lack of uptake of Gd in normal cord tissue, 2) rapid exchange of Gd between plasma and cerebrospinal fluid in both normal and injured cord tissues, and 3) slower uptake of Gd in injured cord. With this approach, it is possible to quantify the integrity of the blood-spinal cord barrier (BSCB) in vivo, evaluate the pathobiology of injured cord, assess the efficacy of interventions, and monitor the progression of injury with postinjury time.
Related Concept Videos
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacodynamic Models: Linear Concentration–Effect Model
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

